Sign up to view this video Join Now Commercialization, • 9/19/25 What Matters to Payers: Conversations You Should Start During Phase 2 Previous Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Next Real-World Evidence That Matters: A Hands-On Workshop in Building Credible Value Stories You Might Also Like Optimizing CRO and Vendor Selection - Examples from the Field Opening Keynote: The Evolving Regulatory Environment for Rare Disease Trials Opening Keynote: The Future of Rare Disease Trials Accelerating Rare Disease Therapies: Strategies for Efficient Clinical Development Ethics and Strategies for Returning Individual Patient Data Collected in Clinical Research
Sign up to view this video Join Now Commercialization, • 9/19/25 What Matters to Payers: Conversations You Should Start During Phase 2 Previous Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Next Real-World Evidence That Matters: A Hands-On Workshop in Building Credible Value Stories You Might Also Like Optimizing CRO and Vendor Selection - Examples from the Field Opening Keynote: The Evolving Regulatory Environment for Rare Disease Trials Opening Keynote: The Future of Rare Disease Trials Accelerating Rare Disease Therapies: Strategies for Efficient Clinical Development Ethics and Strategies for Returning Individual Patient Data Collected in Clinical Research
